RALEIGH – BioDelivery Sciences International Inc. (NASDAQ:BDSI), a specialty pharmaceutical company focused on pain management and addiction medicine, has appointed Herm Cukier CEO and board member.
Former President and CEO, Mark A. Sirgo, will continue his role as vice chair and will work with Cukier on the transition.
Cukier brings extensive commercial leadership experience to BDSI as the company seeks to enhance the growth of its marketed products. He has led a multitude of biopharma businesses to high growth success around the world over the last 25 years. He was most recently a Senior vice [president at Allergan plc, where his roles included being the head of its Eye Care Division, Allergan’s largest division with more than $2.5 billion in annual sales, and the head of its Women’s Healthcare Division, which was one of the fastest growing segments of Allergan under his leadership reaching peak sales of $1.2 billion. He was most recently Allergan’s Head of Commercial Strategy and Innovation.
Cukier said in a statement, “I am thrilled to join BDSI, which I believe is an emerging leader in the field of pain management. There remains tremendous patient need in this therapeutic space with more than 100 million Americans experiencing some form of chronic pain. I look forward to working with the BDSI team to further expand upon the company’s current momentum and continue to build a top performing enterprise.”
